Fresenius SE & Co. KGaA

FRE · Xetra

Public Market Listing

FREXetra

Xetra primary exchange listing

Live quotes, historical charts, and market capitalization for Fresenius SE & Co. KGaA are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
IL-12 p40
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$13.7B$385M$5.0B—report ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$25.9B$718M$4.2B—report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$23.8B$694M$3.6B—report ↗
2023-FY$24.1B$715M$4.1B$161Mreport ↗
2022-FY$22.7B$673M——report ↗